Day Zero Diagnostics

Info

Contact Jong Lee
Title CEO & Co-Founder
Email jong.lee.93@outlook.com
Phone 617-388-8619

Description

Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today. Unlike other molecular diagnostics that can only detect a handful of specific targets, DZD uses the entire genomic sequence and our proprietary Keynome™ algorithm to identify a comprehensive range of bacterial pathogens and their resistance characteristics within hours.

The system includes a benchtop analyzer combined with proprietary single-use sample preparation cartridges. DZD starts with the same clinical samples that are typically sent to the microbiology lab. The system isolates and enriches bacterial DNA, enabling next generation sequencing without the need to wait for culture. The resulting genomes are then analyzed using a cloud-based analytics platform, allowing physicians to treat the patient with the right antibiotic in hours, rather than days.

DZD was founded in May 2016 and is currently a development stage company.   With $3.5M in total funds raised, DZD is targeting the delivery of a prototype in 2018.

Company News

Day Zero Diagnostics: New Diagnostic Rapidly Identifies The Resistance Profile of Bacteria, Enabling Targeted Therapy Sooner

/
DateJan 17, 2018
At the 2017 meeting of AdvaMed, the medical device industry’s advocacy organization, young start-up Day Zero Diagnostics was chosen as this year’s MedTech Innovator Global Competition winner.

Day Zero Diagnostics is 2017 MedTech Innovator Global Competition Winner

/
DateSep 26, 2017
MedTech Innovator announced today Day Zero Diagnostics as the winner of its 2017 global competition. The Boston-based company was selected in a real-time vote by an audience of nearly 1,500 at The MedTech Conference powered by AdvaMed.

Finalists Announced for Annual MedTech Industry $500K Competition

/
DateSep 19, 2017
MedTech Innovator announces that Abreos Biosciences, Allotrope Medical, Day Zero Diagnostics, and Selio Medical will compete in the finals for the vote of the audience of industry leaders September 26 in San Jose, Calif., at The MedTech Conference powered by AdvaMed.